NCT05552222: An ongoing trial by Janssen Research & Development, LLC
This trial is ongoing. It must report results 6 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05552222 |
|---|---|
| Title | A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 25, 2022 |
| Completion date | April 30, 2031 |
| Required reporting date | April 29, 2032, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |